TRASTUZUMABE DERUXTECANA/PROs T-DXd

OC Oncoclínicas RJ

Mama

EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER TREATED WITH TRASTUZUMAB DERUXTECAN IN THE ONCOCLINIS GROUP

Center

OC Oncoclínicas RJ

Principal investigator

Diogo Rodrigues

Email

diogo.rosa@medicos.oncoclinicas.com

Telephone

(21) 2127-0281/82

Inclusion criteria

Female or male patients with HER+ metastatic malignancy of the breast who will start treatment with T-DXd; Age greater than 18 years.

Exclusion criteria

Use of other concomitant antineoplastic therapies;

Patients for whom the physician responsible for prescribing T-DXd is from an institution other than the Oncoclínicas Group.

Coordinator(s)

Tamires Almeida
Share
Or share the link
Link copied to your desktop.